This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks to Watch: Spectrum Pharma, Boeing

NEW YORK -- Spectrum Pharmaceuticals (SPPI - Get Report) warned Tuesday that sales of colon cancer drug Fusilev will be $10 million to $15 million in the first quarter and $80 million to $90 million for all of 2013.

Fusilev sales came in at $44.6 million and $204 million in the fourth quarter and full year 2012, respectively. Spectrum CEO Raj Shrotriya promised investors recently more revenue growth in 2013. But Tuesday the CEO admitted first-quarter Fusilev sales will drop more than 70% sequentially, and will deceline by 60% in 2013.

Spectrum said its total revenue for 2013 is now expected to be in the range of $160 million to $180 million compared with revenue of $268 million in 2012. Analysts were calling for Spectrum to book revenue of $297 million in 2013.

Spectrum Pharma Implodes On Colossal Fusilev Sales Warning


Boeing's (BA - Get Report) plan to redesign the 787 Dreamliner's lithium-ion batteries won approval Tuesday from the Federal Aviation Administration.

Rep. Rick Larsen, D-Wash., who was briefed by the FAA, said that if the tests go well, the FAA could give final approval by mid- to late April for the 787 to resume flight.


Google (GOOG) agreed to pay a $7 million fine to settle with 38 states an investigation into the company's interception of emails, passwords and other sensitive personal information through its Street View cars that collected data from unsecured wireless networks from early 2008 through the spring of 2010.


Velti (VELT) swung to a fourth-quarter loss of more than $5 million and said it expects revenue for the full year of $255 million to $280 million.

Analysts were looking for revenue of $340 million.


Analysts on Wall Street expect Men's Wearhouse (MW - Get Report) on Wednesday to report a fourth-quarter loss of 5 cents a share on revenue of $610 million.

5 Hated Earnings Stocks Poised to Pop


Express (EXPR) is forecast by analysts to post fourth-quarter profit Wednesday of 74 cents a share on revenue of $722.4 million.


-- Written by Joseph Woelfel



>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

Copyright 2013 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BA $148.40 0.00%
GOOG $565.06 0.00%
MW $57.35 0.00%
SPPI $6.10 0.00%
AAPL $130.28 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs